The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease

Author(s): Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, et al.

Abstract

Although circulating tumor necrosis factor (TNF)-alpha levels have been found to be increased in weight-losing patients with chronic obstructive pulmonary disease (COPD), the main causes for this phenomenon remain to be elucidated. Since hypoxia itself can enhance the production of the TNF-alpha in vitro, we studied the relationship between hypoxemia and activities of the TNF-alpha system, including circulating TNF-alpha and soluble TNF-receptors (sTNF-R; sTNF-R55 and -R75) levels, in 27 COPD patients and 15 age-matched healthy controls. The COPD patients showed a significant weight loss (body mass index = 18.1 +/- 2.8 versus 22.8 +/- 2.2 [mean +/- SD] kg/m(2); p < 0.0001. % fat = 16.3 +/- 5.9 versus 24.3 +/- 4.9 %; p < 0.001), and hypoxemia (Pa(O2 )= 62.2 +/- 9.5 versus 88.6 +/- 5.9 mm Hg; p < 0.0001) as compared with the healthy controls. Serum TNF-alpha (6.15 +/- 1.08 versus 5.41 +/- 1.60 pg/ml; p < 0.05) and plasma sTNF-R55 (1.15 +/- 0.49 versus 0.67 +/- 0.13 ng/ml; p < 0.0001) and sTNF-R75 (3.54 +/- 1.16 versus 2.25 +/- 0.43; p < 0.0001) levels were significantly higher in the COPD patients than in the healthy controls. There were inverse correlations between Pa(O(2)) and circulating TNF-alpha and sTNF-R levels in patients with COPD (TNF-alpha; r = -0.426, p = 0.0297; sTNF-R55: r = -0.587, p = 0.0027; sTNF-R75: r = -0.573, p = 0.0035). In addition, we found inverse correlations between sTNF-R levels and % fat in COPD patients (sTNF-R55: r = -0.442, p = 0.0272; sTNF-R75: r = -0. 484, p = 0.0155). TNF-alpha levels correlated well with sTNF-R levels (sTNF-R55: r = 0.488, p = 0.0127; sTNF-R75: r = 0.609, p = 0. 0019). These relationships were not observed in the healthy controls. These data suggest that systemic hypoxemia noted in patients with COPD is associated with activation of the TNF-alpha system in vivo, which may be a factor contributing to the weight loss in patients with the disease.

Similar Articles

Chronic obstructive pulmonary disease surveillance - United States, 1971-2000

Author(s): Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC

Bronchodilators in chronic air-flow limitation

Author(s): Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, et al.

Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD

Author(s): Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, et al.

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Author(s): Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al.

Contemporary management of chronic obstructive pulmonary disease: scientific review

Author(s): Sin DD, McAlister FA, Man SF, Anthonisen NR

Oral theophylline for chronic obstructive pulmonary disease

Author(s): Ram FS, Jones PW, Castro AA, DeBerito JA, Atallah AN, et al.

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

Author(s): Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, et al.

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

Author(s): Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, et al.

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study

Author(s): Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, et al.

Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial

Author(s): Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, et al.

Corticosteroids contribute to muscle weakness in chronic airflow obstruction

Author(s): Decramer M, Lacquet LM, Fagard R, Rogiers P

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

Author(s): Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, et al.

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

Author(s): Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, et al.

Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients

Author(s): Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S

Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease

Author(s): Granger R, Walters J, Poole PJ, Lasserson TJ, Mangtani P, et al.

Marked sympathetic activation in patients with chronic respiratory failure

Author(s): Heindl S, Lehnert M, Criee CP, Hasenfuss G, Andreas S

Appropriateness of domiciliary oxygen delivery

Author(s): Guyatt GH, McKim DA, Austin P, Bryan R, Norgren J, et al.

Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial

Author(s): Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, et al.

Controlled trial of oral prednisone in outpatients with acute COPD exacerbation

Author(s): Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ

Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease

Author(s): Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, et al.

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

Author(s): Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, et al.

Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis

Author(s): Jorgensen AF, Coolidge J, Pedersen PA, Peterson KP, Waldorff S, et al.